Thalidomide therapy in adult patients with myelodysplastic syndrome
| Autor: | Alvaro, Moreno-Aspitia, Gerardo, Colon-Otero, Antje, Hoering, Ayalew, Tefferi, Robert D, Niedringhaus, Allen, Vukov, Chin-Yang, Li, David M, Menke, Susan M, Geyer, Steven R, Alberts |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Pediatrics Cancer Research medicine.medical_specialty Time Factors Constipation Maximum Tolerated Dose Angiogenesis Inhibitors Risk Factors Internal medicine medicine Humans Prospective Studies Adverse effect Aged Aged 80 and over Dose-Response Relationship Drug Adult patients business.industry Myelodysplastic syndromes Cancer Middle Aged medicine.disease Thalidomide Surgery Survival Rate Clinical trial Treatment Outcome Oncology International Prognostic Scoring System Myelodysplastic Syndromes Toxicity Disease Progression Female medicine.symptom business medicine.drug |
| Zdroj: | Cancer. 107:767-772 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/cncr.22047 |
| Popis: | BACKGROUND. Thalidomide has shown promise for the treatment of patients with myelodysplastic syndrome. The current prospective multicenter study examined the efficacy and toxicity of thalidomide in adult patients with myelodysplastic syndrome. METHODS. Using the International Prognostic Scoring System (IPSS), patients were stratified into 2 groups: favorable (IPSS score, 0–1.0) or unfavorable (IPSS score, 1.5–3.5). Seventy-two patients (42 of whom were favorable and 30 of whom were unfavorable) received a starting dose of oral thalidomide of 200 mg daily. The dose was increased by 50 mg per week to a targeted maximum daily dose of 1000 mg. RESULTS. According to the International Working Group response criteria for myelodysplastic syndrome, 1 patient in the unfavorable group achieved a partial remission with a complete cytogenetic response. Overall, 2 patients (5%) in the favorable group and 4 patients (14%) in the unfavorable group experienced either a hematologic improvement or a partial response. The most frequent Grade 3 or 4 (grading was based on the National Cancer Institute's Common Toxicity Criteria [version 2.0]) nonhematologic adverse events were fatigue (24%), infection (19%), neuropathy (13%), dyspnea (8%), and constipation (7%). CONCLUSIONS. Thalidomide alone, at the schedule and dose levels used in the current study, is not a safe and viable therapeutic option for patients with myelodysplastic syndrome. Limited efficacy and increased toxicity were observed in the current Phase II trial. Cancer 2006. © 2006 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text